Hims CEO reveals details of Novo Nordisk partnership breakdown - WaPo

Published 14/07/2025, 18:00
© Reuters.

Investing.com -- Hims & Hers CEO Andrew Dudum has shared new information about the company’s terminated partnership with Novo Nordisk (NYSE:NVO), which ended in June 2025, in an interview with The Washington Post.

According to Dudum, the relationship deteriorated shortly after an April 11 meeting where Hims executives discussed with Novo Nordisk their plans to continue offering "personalized" doses of compounded semaglutide alongside Wegovy. Dudum claimed there was "no hearty debate" on this issue during the meeting, though he acknowledged Novo showed dissatisfaction with Hims not dropping compounded semaglutide entirely.

The companies had been discussing a new product arrangement where Novo would produce Wegovy vials for Hims to sell under its own brand. However, Dudum said Novo’s position changed within days of their meeting, with his team suddenly facing pressure to prioritize Wegovy over compounded alternatives.

Novo Nordisk ultimately terminated the partnership in June, accusing Hims of illegally selling compounded versions of Wegovy and using deceptive marketing practices. The Danish drugmaker released what Dudum described as a "scathing press release" without prior notification, leaving him feeling "blindsided."

Hims & Hers has denied Novo’s allegations, instead claiming the pharmaceutical company pressured them to prioritize Wegovy over patient needs. The dispute triggered a 30-35% drop in Hims’ stock price and has sparked potential legal action, including a class action lawsuit against Hims for allegedly misleading investors about safety and operational risks.

When asked about Dudum’s account, Novo declined to comment on specific conversations, stating only that "We don’t disclose private business conversations" and that "Every company we work with is aware of our stance and expectations."

Despite the contentious split, Dudum said he wouldn’t rule out working with Novo Nordisk in the future. Hims & Hers continues to offer Wegovy on its platform at retail price.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.